

# Cynthia M Westerhout

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7699389/publications.pdf>

Version: 2024-02-01

95  
papers

3,381  
citations

147566

31  
h-index

149479

56  
g-index

96  
all docs

96  
docs citations

96  
times ranked

3896  
citing authors

#	ARTICLE	IF	CITATIONS
1	Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery. <i>Circulation</i> , 2003, 107, 1848-1851.	1.6	465
2	Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. <i>American Journal of Medicine</i> , 2004, 116, 96-103.	0.6	242
3	Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. <i>European Heart Journal</i> , 2010, 31, 1701-1707.	1.0	199
4	ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2008, 118, 1335-1346.	1.6	146
5	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 231-242.	0.4	110
6	Acute heart failure in the emergency department: Short and long-term outcomes of elderly patients with heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 308-314.	2.9	104
7	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	1.9	88
8	Impact of Sex on Long-term Mortality From Acute Myocardial Infarction vs Unstable Angina. <i>Archives of Internal Medicine</i> , 2003, 163, 2476.	4.3	85
9	The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. <i>American Heart Journal</i> , 2011, 161, 283-290.	1.2	85
10	Composite End Points in Clinical Research. <i>Circulation</i> , 2017, 135, 2299-2307.	1.6	79
11	Primary Percutaneous Coronary Intervention Compared With Fibrinolysis for Myocardial Infarction in Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2007, 167, 1353.	4.3	73
12	Short- and Long-Term Risk Stratification in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2006, 48, 939-947.	1.2	71
13	Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 343-351.	1.1	69
14	Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1503-1509.	1.2	67
15	Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes. <i>Cmaj</i> , 2007, 177, 1193-1199.	0.9	63
16	Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. <i>European Heart Journal</i> , 2010, 31, 1708-1716.	1.0	63
17	Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 78-86.	2.2	52
18	Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study. <i>European Heart Journal</i> , 2008, 29, 1127-1135.	1.0	49

#	ARTICLE	IF	CITATIONS
19	Mortality and Morbidity Reduction by Primary Percutaneous Coronary Intervention Is Independent of the Patient's Age. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 324-331.	1.1	47
20	Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials. <i>Statistical Methods in Medical Research</i> , 2015, 24, 980-988.	0.7	46
21	Sex differences in patients seeking medical attention for prodromal symptoms before an acute coronary event. <i>American Heart Journal</i> , 2008, 156, 1210-1216.e1.	1.2	45
22	Refining clinical trial composite outcomes: An application to the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-3) trial. <i>American Heart Journal</i> , 2011, 161, 848-854.	1.2	45
23	Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. <i>European Heart Journal</i> , 2015, 36, 385-392.	1.0	44
24	Effects of Socioeconomic Status on Mortality after Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2007, 120, 33-39.	0.6	43
25	ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation</i> , 2012, 125, 514-521.	1.6	39
26	Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 166-174.	1.1	39
27	Duration of Symptoms Is the Key Modulator of the Choice of Reperfusion for ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2009, 119, 1293-1303.	1.6	36
28	High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration. <i>American Heart Journal</i> , 2011, 161, 500-507.e1.	1.2	36
29	Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008059.	1.4	35
30	Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early) <i>Tj ETQq0 0 0 rgBT (Overlock 14 Tf 50 29</i>	1.0	34
31	Usefulness of the QRS Score as a Strong Prognostic Marker in Patients Discharged After Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 106, 630-634.	0.7	33
32	Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. <i>European Heart Journal</i> , 2006, 27, 419-426.	1.0	29
33	Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. <i>Journal of Epidemiology and Community Health</i> , 2005, 59, 427-433.	2.0	28
34	Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 573-581.	1.0	28
35	Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. <i>European Heart Journal</i> , 2013, 34, 903-908.	1.0	28
36	Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 735-741.	1.6	27

#	ARTICLE	IF	CITATIONS
37	Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. <i>Cmaj</i> , 2012, 184, 1135-1142.	0.9	26
38	Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STRategic Reperfusion Early After Myocardial infarction trial. <i>American Heart Journal</i> , 2015, 169, 890-898.e1.	1.2	26
39	Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women. <i>European Heart Journal</i> , 2007, 28, 2064-2069.	1.0	24
40	Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. <i>Heart</i> , 2015, 101, 692-698.	1.2	23
41	Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. <i>American Heart Journal</i> , 2013, 166, 723-728.	1.2	22
42	Dietary fatty acids intake and mortality in patients with heart failure. <i>Nutrition</i> , 2014, 30, 1366-1371.	1.1	22
43	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	1.6	21
44	Long-Term Outcomes of Complete Revascularization With Percutaneous Coronary Intervention in Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1557-1567.	1.1	20
45	The forgotten lead: Does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?. <i>American Heart Journal</i> , 2013, 166, 333-339.	1.2	19
46	Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. <i>American Heart Journal</i> , 2010, 160, 671-677.	1.2	18
47	Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. <i>American Heart Journal</i> , 2013, 165, 583-590.e1.	1.2	18
48	Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. <i>Journal of Electrocardiology</i> , 2010, 43, 351-358.	0.4	17
49	Relative Prognostic Value of Baseline Q Wave and Time from Symptom Onset Among Men and Women With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 110, 1555-1560.	0.7	17
50	Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. <i>Heart</i> , 2007, 93, 450-455.	1.2	16
51	A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: A WEST sub-study. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 341-348.	0.7	16
52	Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2006, 27, 2956-2961.	1.0	15
53	Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2014, 168, 182-188.e1.	1.2	14
54	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 840-846.	0.8	14

#	ARTICLE	IF	CITATIONS
55	The relationship between meteorological conditions and index acute coronary events in a global clinical trial. <i>International Journal of Cardiology</i> , 2013, 168, 2315-2321.	0.8	13
56	Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the Strategic Reperfusion Early After Myocardial infarction trial. <i>Heart</i> , 2014, 100, 1543-1549.	1.2	13
57	Participation in a Heart Failure Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008242.	1.6	12
58	Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library. <i>Contemporary Clinical Trials</i> , 2008, 29, 887-895.	0.8	11
59	Mode of hospital presentation in patients with non-ST-elevation myocardial infarction: Implications for strategic management. <i>American Heart Journal</i> , 2011, 162, 436-443.	1.2	11
60	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). <i>Canadian Journal of Cardiology</i> , 2014, 30, 1208-1215.	0.8	11
61	Hospital variation in treatment and outcomes in acute coronary syndromes: Insights from the Alberta Contemporary Acute Coronary Syndrome Patients Invasive Treatment Strategies (COAPT) study. <i>International Journal of Cardiology</i> , 2017, 241, 70-75.	0.8	11
62	Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. <i>American Heart Journal</i> , 2010, 159, 899-904.	1.2	10
63	Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. <i>Heart</i> , 2015, 101, 1554-1561.	1.2	10
64	Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex. <i>American Journal of Medicine</i> , 2015, 128, 914.e11-914.e19.	0.6	10
65	Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2013, 165, 354-362.e2.	1.2	9
66	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 819-824.	0.8	9
67	Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction. <i>Journal of Electrocardiology</i> , 2014, 47, 465-471.	0.4	9
68	Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 49-58.	1.0	8
69	Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. <i>American Heart Journal</i> , 2009, 158, 755-760.	1.2	8
70	Association of global weather changes with acute coronary syndromes: gaining insights from clinical trials data. <i>International Journal of Biometeorology</i> , 2013, 57, 401-408.	1.3	8
71	Efficacy and Safety of Vorapaxar in Non-ST-segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	8
72	Relationship between community hospital versus pre-hospital location of randomisation and clinical outcomes in ST-elevation myocardial infarction patients: insights from the Stream study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 504-513.	0.4	8

#	ARTICLE	IF	CITATIONS
73	Guideline adjudicated fibrinolytic failure: Incidence, findings, and management in a contemporary clinical trial. <i>American Heart Journal</i> , 2008, 155, 121-127.	1.2	7
74	Aborted myocardial infarction after primary percutaneous coronary intervention: Magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. <i>American Heart Journal</i> , 2013, 165, 226-233.	1.2	7
75	Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 163-173.	0.7	7
76	Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy. <i>American Journal of Medicine</i> , 2013, 126, 723-729.e1.	0.6	6
77	The Power of More Than One. <i>Circulation</i> , 2013, 127, 665-667.	1.6	6
78	Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. <i>American Heart Journal</i> , 2014, 168, 757-765.e3.	1.2	6
79	High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2020, 220, 137-144.	1.2	6
80	Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTEMI/ACS) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTEMI/ACS (EARLYACS) trial. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 934-942.	0.7	5
81	Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. <i>American Heart Journal</i> , 2017, 188, 127-135.	1.2	5
82	Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 126-131.	1.0	4
83	Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. <i>Heart</i> , 2016, 102, 527-533.	1.2	4
84	Utilization and Costs of Noninvasive Cardiac Tests After Acute Coronary Syndromes: Insights From the Alberta COAPT Study. <i>CJC Open</i> , 2019, 1, 76-83.	0.7	4
85	Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2020, 9, e016033.	1.6	4
86	No prognostic significance of chronic infection with <i>Chlamydia pneumoniae</i> in acute coronary syndromes: Insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2007, 154, 306-312.	1.2	2
87	ST-Segment Resolution and Outcome in Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1646-1647.	1.2	2
88	Novel approaches to composite endpoints in clinical trials. <i>EuroIntervention</i> , 2015, 11, 122-124.	1.4	2
89	An assessment of ST-segment measurement variability between two core electrocardiogram laboratories. <i>Journal of Electrocardiology</i> , 2014, 47, 38-44.	0.4	1
90	Traveling the Interstices of Data Sharing. <i>JACC: Heart Failure</i> , 2018, 6, 533-535.	1.9	1

#	ARTICLE	IF	CITATIONS
91	Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis. JAMA Cardiology, 2020, 5, 1286.	3.0	1
92	Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. , 0, .		1
93	Interinstitutional variation in the use of abciximab for percutaneous coronary intervention. Canadian Journal of Cardiology, 2004, 20, 405-10.	0.8	1
94	ST Elevation Acute Coronary Syndromes in PLATO. Circulation, 2011, , 1.	1.6	0
95	Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure?. Journal of Cardiac Failure, 2021, 27, 934-941.	0.7	0